GlassScriptPhysician profile
Roel M Laygo
NPI 1265471122
$10,626.58
in general payments reported to CMS, 2019-2025
52 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $505 · 2021: $2,372 · 2022: $2,086 · 2023: $1,351 · 2024: $1,820 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,392.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.22 | 2021-2025 | |
| Novo Nordisk INC | $1,261.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,051.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $848.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $531.12 | 2019-2025 | |
| Lilly USA, LLC | $501.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.16 | 2019-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $369.03 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $290.44 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $290.04 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.33 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $280.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $249.59 | 2020-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $206.01 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $192.14 | 2023-2025 | Myfembree, Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roel Laygo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.